tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

ITOS Stock Latest News

iTeos Therapeutics announces first patient dosed in GALAXIES Lung-301 study
The FlyiTeos Therapeutics announces first patient dosed in GALAXIES Lung-301 study
19d ago
GSK
ITOS
iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK
PremiumPress Releases
iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK
19d ago
ITOS
iTeos Therapeutics, GSK initiate GALAXIES Lung-301 Phase 3 study
PremiumThe Fly
iTeos Therapeutics, GSK initiate GALAXIES Lung-301 Phase 3 study
1M ago
GSK
ITOS
iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer
PremiumPress Releases
iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer
1M ago
ITOS
iTeos Therapeutics (NASDAQ:ITOS): Harnessing the Power of Immunotherapy
PremiumMarket News
iTeos Therapeutics (NASDAQ:ITOS): Harnessing the Power of Immunotherapy
2M ago
ITOS
iTeos Therapeutics price target raised to $46 from $44 at H.C. Wainwright
PremiumThe FlyiTeos Therapeutics price target raised to $46 from $44 at H.C. Wainwright
2M ago
ITOS
iTeos Therapeutics to sell 1.14M shares at $17.50 in registered direct offering
PremiumThe Fly
iTeos Therapeutics to sell 1.14M shares at $17.50 in registered direct offering
3M ago
ITOS
iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates
PremiumPress Releases
iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates
3M ago
ITOS
iTeos Therapeutics sees cash runway through 2027
PremiumThe Fly
iTeos Therapeutics sees cash runway through 2027
3M ago
ITOS
iTeos Therapeutics reports Q1 EPS ($1.07), consensus ($1.26)
PremiumThe Fly
iTeos Therapeutics reports Q1 EPS ($1.07), consensus ($1.26)
3M ago
ITOS
iTeos Therapeutics Announces $120 Million Registered Direct Offering
PremiumPress Releases
iTeos Therapeutics Announces $120 Million Registered Direct Offering
3M ago
ITOS
iTeos Therapeutics presents preclinical data on EOS-984
PremiumThe Fly
iTeos Therapeutics presents preclinical data on EOS-984
4M ago
ITOS
iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024
PremiumPress ReleasesiTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024
4M ago
ITOS
iTeos Therapeutics management to meet with Piper Sandler
PremiumThe Fly
iTeos Therapeutics management to meet with Piper Sandler
5M ago
ITOS
iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
PremiumPress Releases
iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
5M ago
ITOS
iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors
PremiumPress Releases
iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors
5M ago
ITOS
iTeos Therapeutics reports Q4 EPS (85c), consensus ($1.03)
PremiumThe Fly
iTeos Therapeutics reports Q4 EPS (85c), consensus ($1.03)
5M ago
ITOS
iTeos Therapeutics appoints DeSimone to board of directors
PremiumThe Fly
iTeos Therapeutics appoints DeSimone to board of directors
5M ago
MRK
ITOS
iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024
PremiumPress Releases
iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024
5M ago
ITOS
iTeos to Participate in Upcoming Investor Conferences
PremiumPress ReleasesiTeos to Participate in Upcoming Investor Conferences
5M ago
ITOS
iTeos Therapeutics announces 2024 strategic priorities, anticipated milestones
PremiumThe Fly
iTeos Therapeutics announces 2024 strategic priorities, anticipated milestones
7M ago
ITOS
iTeos to Present at the Piper Sandler 35th Annual Healthcare Conference
PremiumPress Releases
iTeos to Present at the Piper Sandler 35th Annual Healthcare Conference
8M ago
ITOS

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >